Lilly says weight loss drug cuts heart failure risk by 38% in trial - Reuters
- Lilly says weight loss drug cuts heart failure risk by 38% in trial Reuters
- Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and Company
- Live news: Tech sell-off drags Nasdaq and S&P 500 lower Financial Times
- Eli Lilly says tirzepatide showed positive results in late-stage trial evaluating it as treatment for heart failure MarketWatch